nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—DDR2—connective tissue—salivary gland cancer	0.00871	0.0318	CbGeAlD
Regorafenib—FRK—lymphoid tissue—salivary gland cancer	0.0071	0.0259	CbGeAlD
Regorafenib—EPHX2—parotid gland—salivary gland cancer	0.00669	0.0244	CbGeAlD
Regorafenib—RET—neck—salivary gland cancer	0.00654	0.0239	CbGeAlD
Regorafenib—DDR2—lymphoid tissue—salivary gland cancer	0.00637	0.0232	CbGeAlD
Regorafenib—FGFR2—neck—salivary gland cancer	0.00621	0.0227	CbGeAlD
Regorafenib—FLT1—neck—salivary gland cancer	0.00576	0.021	CbGeAlD
Regorafenib—RAF1—neck—salivary gland cancer	0.00572	0.0209	CbGeAlD
Regorafenib—FLT4—epithelium—salivary gland cancer	0.00504	0.0184	CbGeAlD
Regorafenib—EPHA2—parotid gland—salivary gland cancer	0.00497	0.0181	CbGeAlD
Regorafenib—KDR—neck—salivary gland cancer	0.00487	0.0178	CbGeAlD
Regorafenib—FGFR2—saliva-secreting gland—salivary gland cancer	0.00484	0.0177	CbGeAlD
Regorafenib—EPHA2—saliva-secreting gland—salivary gland cancer	0.00476	0.0174	CbGeAlD
Regorafenib—FLT1—parotid gland—salivary gland cancer	0.00469	0.0171	CbGeAlD
Regorafenib—RET—connective tissue—salivary gland cancer	0.00468	0.0171	CbGeAlD
Regorafenib—RAF1—parotid gland—salivary gland cancer	0.00466	0.017	CbGeAlD
Regorafenib—FLT1—saliva-secreting gland—salivary gland cancer	0.00449	0.0164	CbGeAlD
Regorafenib—RAF1—saliva-secreting gland—salivary gland cancer	0.00446	0.0163	CbGeAlD
Regorafenib—FGFR2—connective tissue—salivary gland cancer	0.00445	0.0162	CbGeAlD
Regorafenib—RET—epithelium—salivary gland cancer	0.00445	0.0162	CbGeAlD
Regorafenib—KIT—neck—salivary gland cancer	0.00431	0.0157	CbGeAlD
Regorafenib—TEK—connective tissue—salivary gland cancer	0.00427	0.0156	CbGeAlD
Regorafenib—FGFR2—epithelium—salivary gland cancer	0.00423	0.0154	CbGeAlD
Regorafenib—PDGFRB—neck—salivary gland cancer	0.00421	0.0154	CbGeAlD
Regorafenib—EPHA2—epithelium—salivary gland cancer	0.00415	0.0152	CbGeAlD
Regorafenib—FLT1—connective tissue—salivary gland cancer	0.00413	0.0151	CbGeAlD
Regorafenib—RAF1—connective tissue—salivary gland cancer	0.0041	0.015	CbGeAlD
Regorafenib—TEK—epithelium—salivary gland cancer	0.00405	0.0148	CbGeAlD
Regorafenib—KDR—parotid gland—salivary gland cancer	0.00396	0.0145	CbGeAlD
Regorafenib—FLT1—epithelium—salivary gland cancer	0.00392	0.0143	CbGeAlD
Regorafenib—RAF1—epithelium—salivary gland cancer	0.00389	0.0142	CbGeAlD
Regorafenib—FLT4—lymphoid tissue—salivary gland cancer	0.00388	0.0142	CbGeAlD
Regorafenib—PDGFRA—connective tissue—salivary gland cancer	0.00387	0.0141	CbGeAlD
Regorafenib—KDR—saliva-secreting gland—salivary gland cancer	0.0038	0.0139	CbGeAlD
Regorafenib—DDR2—lymph node—salivary gland cancer	0.00359	0.0131	CbGeAlD
Regorafenib—KIT—parotid gland—salivary gland cancer	0.00351	0.0128	CbGeAlD
Regorafenib—KDR—connective tissue—salivary gland cancer	0.00349	0.0127	CbGeAlD
Regorafenib—PDGFRB—parotid gland—salivary gland cancer	0.00343	0.0125	CbGeAlD
Regorafenib—RET—lymphoid tissue—salivary gland cancer	0.00343	0.0125	CbGeAlD
Regorafenib—MAPK11—lymph node—salivary gland cancer	0.00341	0.0124	CbGeAlD
Regorafenib—KIT—saliva-secreting gland—salivary gland cancer	0.00336	0.0123	CbGeAlD
Regorafenib—KDR—epithelium—salivary gland cancer	0.00331	0.0121	CbGeAlD
Regorafenib—PDGFRB—saliva-secreting gland—salivary gland cancer	0.00329	0.012	CbGeAlD
Regorafenib—EPHA2—lymphoid tissue—salivary gland cancer	0.0032	0.0117	CbGeAlD
Regorafenib—TEK—lymphoid tissue—salivary gland cancer	0.00312	0.0114	CbGeAlD
Regorafenib—KIT—connective tissue—salivary gland cancer	0.00309	0.0113	CbGeAlD
Regorafenib—ABL1—parotid gland—salivary gland cancer	0.00306	0.0112	CbGeAlD
Regorafenib—PDGFRB—connective tissue—salivary gland cancer	0.00302	0.011	CbGeAlD
Regorafenib—FLT1—lymphoid tissue—salivary gland cancer	0.00302	0.011	CbGeAlD
Regorafenib—RAF1—lymphoid tissue—salivary gland cancer	0.003	0.0109	CbGeAlD
Regorafenib—KIT—epithelium—salivary gland cancer	0.00293	0.0107	CbGeAlD
Regorafenib—ABL1—saliva-secreting gland—salivary gland cancer	0.00293	0.0107	CbGeAlD
Regorafenib—PDGFRB—epithelium—salivary gland cancer	0.00287	0.0105	CbGeAlD
Regorafenib—PDGFRA—lymphoid tissue—salivary gland cancer	0.00283	0.0103	CbGeAlD
Regorafenib—ABL1—connective tissue—salivary gland cancer	0.00269	0.00982	CbGeAlD
Regorafenib—KDR—lymphoid tissue—salivary gland cancer	0.00255	0.00931	CbGeAlD
Regorafenib—BRAF—lymph node—salivary gland cancer	0.00254	0.00927	CbGeAlD
Regorafenib—EPHX2—lymph node—salivary gland cancer	0.00243	0.00886	CbGeAlD
Regorafenib—KIT—lymphoid tissue—salivary gland cancer	0.00226	0.00825	CbGeAlD
Regorafenib—PDGFRB—lymphoid tissue—salivary gland cancer	0.00221	0.00805	CbGeAlD
Regorafenib—FLT4—lymph node—salivary gland cancer	0.00219	0.00799	CbGeAlD
Regorafenib—FGFR1—lymph node—salivary gland cancer	0.00216	0.00788	CbGeAlD
Regorafenib—ABL1—lymphoid tissue—salivary gland cancer	0.00197	0.00718	CbGeAlD
Regorafenib—RET—lymph node—salivary gland cancer	0.00193	0.00705	CbGeAlD
Regorafenib—ABCG2—parotid gland—salivary gland cancer	0.00193	0.00704	CbGeAlD
Regorafenib—ABCG2—saliva-secreting gland—salivary gland cancer	0.00185	0.00674	CbGeAlD
Regorafenib—EPHA2—lymph node—salivary gland cancer	0.0018	0.00659	CbGeAlD
Regorafenib—TEK—lymph node—salivary gland cancer	0.00176	0.00642	CbGeAlD
Regorafenib—FLT1—lymph node—salivary gland cancer	0.0017	0.00621	CbGeAlD
Regorafenib—RAF1—lymph node—salivary gland cancer	0.00169	0.00618	CbGeAlD
Regorafenib—PDGFRA—lymph node—salivary gland cancer	0.0016	0.00582	CbGeAlD
Regorafenib—KDR—lymph node—salivary gland cancer	0.00144	0.00525	CbGeAlD
Regorafenib—KIT—lymph node—salivary gland cancer	0.00128	0.00465	CbGeAlD
Regorafenib—PDGFRB—lymph node—salivary gland cancer	0.00125	0.00454	CbGeAlD
Regorafenib—CYP2B6—lymphoid tissue—salivary gland cancer	0.00114	0.00418	CbGeAlD
Regorafenib—ABL1—lymph node—salivary gland cancer	0.00111	0.00405	CbGeAlD
Regorafenib—ABCB1—epithelium—salivary gland cancer	0.000794	0.0029	CbGeAlD
Regorafenib—ABCG2—lymph node—salivary gland cancer	0.0007	0.00255	CbGeAlD
Regorafenib—ABCB1—lymphoid tissue—salivary gland cancer	0.000612	0.00223	CbGeAlD
Regorafenib—ABCB1—lymph node—salivary gland cancer	0.000345	0.00126	CbGeAlD
Regorafenib—FGFR1—Signaling Pathways—MAP2K2—salivary gland cancer	2.67e-05	3.68e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—CDH1—salivary gland cancer	2.67e-05	3.67e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—MAP2K2—salivary gland cancer	2.66e-05	3.67e-05	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—PIK3CA—salivary gland cancer	2.65e-05	3.66e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—NUP62—salivary gland cancer	2.65e-05	3.65e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—PIK3CA—salivary gland cancer	2.65e-05	3.65e-05	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—TP53—salivary gland cancer	2.65e-05	3.65e-05	CbGpPWpGaD
Regorafenib—FGFR2—Innate Immune System—HRAS—salivary gland cancer	2.63e-05	3.63e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—VCAN—salivary gland cancer	2.63e-05	3.62e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—FOXO3—salivary gland cancer	2.62e-05	3.61e-05	CbGpPWpGaD
Regorafenib—KIT—Innate Immune System—HRAS—salivary gland cancer	2.59e-05	3.56e-05	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—PIK3CA—salivary gland cancer	2.58e-05	3.56e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—PTEN—salivary gland cancer	2.56e-05	3.53e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—NOTCH1—salivary gland cancer	2.56e-05	3.52e-05	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—PIK3CA—salivary gland cancer	2.55e-05	3.51e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—CREBBP—salivary gland cancer	2.55e-05	3.51e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—PIK3CA—salivary gland cancer	2.54e-05	3.5e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—NOTCH1—salivary gland cancer	2.53e-05	3.49e-05	CbGpPWpGaD
Regorafenib—FLT4—Signaling Pathways—HRAS—salivary gland cancer	2.53e-05	3.49e-05	CbGpPWpGaD
Regorafenib—FGFR2—Adaptive Immune System—HRAS—salivary gland cancer	2.53e-05	3.48e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PYGB—salivary gland cancer	2.52e-05	3.47e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—NOTCH1—salivary gland cancer	2.5e-05	3.45e-05	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—TP53—salivary gland cancer	2.5e-05	3.44e-05	CbGpPWpGaD
Regorafenib—KIT—Adaptive Immune System—HRAS—salivary gland cancer	2.48e-05	3.42e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CREBBP—salivary gland cancer	2.46e-05	3.38e-05	CbGpPWpGaD
Regorafenib—FGFR1—Innate Immune System—HRAS—salivary gland cancer	2.46e-05	3.38e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Innate Immune System—HRAS—salivary gland cancer	2.45e-05	3.37e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—EP300—salivary gland cancer	2.44e-05	3.36e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—CDH1—salivary gland cancer	2.44e-05	3.36e-05	CbGpPWpGaD
Regorafenib—ABL1—Developmental Biology—HRAS—salivary gland cancer	2.43e-05	3.35e-05	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—salivary gland cancer	2.43e-05	3.34e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—MAP2K2—salivary gland cancer	2.4e-05	3.3e-05	CbGpPWpGaD
Regorafenib—ABL1—Hemostasis—HRAS—salivary gland cancer	2.39e-05	3.29e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—PIK3CA—salivary gland cancer	2.38e-05	3.28e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—NUP62—salivary gland cancer	2.37e-05	3.26e-05	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—PIK3CA—salivary gland cancer	2.36e-05	3.25e-05	CbGpPWpGaD
Regorafenib—FGFR1—Adaptive Immune System—HRAS—salivary gland cancer	2.36e-05	3.25e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Adaptive Immune System—HRAS—salivary gland cancer	2.35e-05	3.24e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—PTEN—salivary gland cancer	2.35e-05	3.24e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—VCAN—salivary gland cancer	2.35e-05	3.24e-05	CbGpPWpGaD
Regorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—salivary gland cancer	2.35e-05	3.23e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—NOTCH1—salivary gland cancer	2.35e-05	3.23e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—PTEN—salivary gland cancer	2.34e-05	3.23e-05	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—PIK3CA—salivary gland cancer	2.32e-05	3.2e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CREBBP—salivary gland cancer	2.32e-05	3.19e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—NUP62—salivary gland cancer	2.31e-05	3.18e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—salivary gland cancer	2.31e-05	3.18e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—PTEN—salivary gland cancer	2.31e-05	3.18e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—NOTCH1—salivary gland cancer	2.31e-05	3.18e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CREBBP—salivary gland cancer	2.3e-05	3.16e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—VCAN—salivary gland cancer	2.29e-05	3.16e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—PIK3CA—salivary gland cancer	2.29e-05	3.15e-05	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—TP53—salivary gland cancer	2.28e-05	3.15e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—CREBBP—salivary gland cancer	2.27e-05	3.12e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—EP300—salivary gland cancer	2.24e-05	3.09e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—EP300—salivary gland cancer	2.23e-05	3.08e-05	CbGpPWpGaD
Regorafenib—RAF1—Developmental Biology—HRAS—salivary gland cancer	2.23e-05	3.07e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	2.21e-05	3.04e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Innate Immune System—HRAS—salivary gland cancer	2.21e-05	3.04e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—EP300—salivary gland cancer	2.2e-05	3.03e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—PTEN—salivary gland cancer	2.19e-05	3.02e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—NOTCH1—salivary gland cancer	2.19e-05	3.01e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—PTEN—salivary gland cancer	2.19e-05	3.01e-05	CbGpPWpGaD
Regorafenib—RAF1—Hemostasis—HRAS—salivary gland cancer	2.18e-05	3.01e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—NOTCH1—salivary gland cancer	2.18e-05	3.01e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—PTEN—salivary gland cancer	2.17e-05	2.99e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—NUP62—salivary gland cancer	2.16e-05	2.97e-05	CbGpPWpGaD
Regorafenib—ABL1—Innate Immune System—HRAS—salivary gland cancer	2.15e-05	2.96e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—VCAN—salivary gland cancer	2.14e-05	2.95e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—MAP2K2—salivary gland cancer	2.14e-05	2.95e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—PTEN—salivary gland cancer	2.13e-05	2.94e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CREBBP—salivary gland cancer	2.13e-05	2.93e-05	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—PIK3CA—salivary gland cancer	2.13e-05	2.93e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Adaptive Immune System—HRAS—salivary gland cancer	2.12e-05	2.92e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—CCND1—salivary gland cancer	2.11e-05	2.91e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CREBBP—salivary gland cancer	2.09e-05	2.88e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—EP300—salivary gland cancer	2.09e-05	2.88e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—EP300—salivary gland cancer	2.08e-05	2.87e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—EP300—salivary gland cancer	2.07e-05	2.85e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—salivary gland cancer	2.06e-05	2.84e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PHGDH—salivary gland cancer	2.05e-05	2.83e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—PIK3CA—salivary gland cancer	2.04e-05	2.81e-05	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—PIK3CA—salivary gland cancer	2.04e-05	2.81e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—PTEN—salivary gland cancer	2.04e-05	2.81e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—EP300—salivary gland cancer	2.03e-05	2.8e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—PTEN—salivary gland cancer	2.02e-05	2.79e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—PTEN—salivary gland cancer	2.02e-05	2.78e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—CCND1—salivary gland cancer	1.99e-05	2.75e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CREBBP—salivary gland cancer	1.98e-05	2.73e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CREBBP—salivary gland cancer	1.98e-05	2.73e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—ST3GAL4—salivary gland cancer	1.98e-05	2.72e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—TP53—salivary gland cancer	1.97e-05	2.72e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—PTEN—salivary gland cancer	1.97e-05	2.71e-05	CbGpPWpGaD
Regorafenib—RAF1—Innate Immune System—HRAS—salivary gland cancer	1.97e-05	2.71e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—NOTCH1—salivary gland cancer	1.97e-05	2.71e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—CREBBP—salivary gland cancer	1.95e-05	2.69e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—CREBBP—salivary gland cancer	1.95e-05	2.69e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—EP300—salivary gland cancer	1.94e-05	2.68e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—EP300—salivary gland cancer	1.93e-05	2.66e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—PTEN—salivary gland cancer	1.92e-05	2.65e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—EP300—salivary gland cancer	1.92e-05	2.65e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—PTEN—salivary gland cancer	1.92e-05	2.64e-05	CbGpPWpGaD
Regorafenib—ABCB1—Transmembrane transport of small molecules—CREBBP—salivary gland cancer	1.91e-05	2.63e-05	CbGpPWpGaD
Regorafenib—FLT1—Signaling Pathways—HRAS—salivary gland cancer	1.89e-05	2.6e-05	CbGpPWpGaD
Regorafenib—RAF1—Adaptive Immune System—HRAS—salivary gland cancer	1.89e-05	2.6e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—salivary gland cancer	1.88e-05	2.59e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—EP300—salivary gland cancer	1.88e-05	2.59e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—EP300—salivary gland cancer	1.84e-05	2.53e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—EP300—salivary gland cancer	1.83e-05	2.52e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—PTEN—salivary gland cancer	1.82e-05	2.5e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—PIK3CA—salivary gland cancer	1.81e-05	2.49e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—AQP1—salivary gland cancer	1.8e-05	2.47e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CREBBP—salivary gland cancer	1.78e-05	2.46e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—PTEN—salivary gland cancer	1.75e-05	2.42e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—NOTCH1—salivary gland cancer	1.75e-05	2.41e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—EP300—salivary gland cancer	1.73e-05	2.39e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—CCND1—salivary gland cancer	1.71e-05	2.36e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—CCND1—salivary gland cancer	1.7e-05	2.34e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—EP300—salivary gland cancer	1.67e-05	2.31e-05	CbGpPWpGaD
Regorafenib—MAPK11—Immune System—HRAS—salivary gland cancer	1.67e-05	2.3e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—PIK3CA—salivary gland cancer	1.66e-05	2.28e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—CREBBP—salivary gland cancer	1.66e-05	2.28e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—PTEN—salivary gland cancer	1.66e-05	2.28e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—PIK3CA—salivary gland cancer	1.65e-05	2.28e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	1.65e-05	2.27e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—PTEN—salivary gland cancer	1.64e-05	2.26e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—PIK3CA—salivary gland cancer	1.63e-05	2.24e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—PTEN—salivary gland cancer	1.62e-05	2.23e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CREBBP—salivary gland cancer	1.59e-05	2.19e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—EP300—salivary gland cancer	1.58e-05	2.17e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—CCND1—salivary gland cancer	1.57e-05	2.17e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	1.57e-05	2.17e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—EP300—salivary gland cancer	1.56e-05	2.15e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—CCND1—salivary gland cancer	1.55e-05	2.13e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—PIK3CA—salivary gland cancer	1.55e-05	2.13e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—EP300—salivary gland cancer	1.55e-05	2.13e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—PIK3CA—salivary gland cancer	1.54e-05	2.12e-05	CbGpPWpGaD
Regorafenib—FGFR2—Immune System—HRAS—salivary gland cancer	1.53e-05	2.11e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—PIK3CA—salivary gland cancer	1.53e-05	2.11e-05	CbGpPWpGaD
Regorafenib—BRAF—Disease—HRAS—salivary gland cancer	1.53e-05	2.11e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—PTEN—salivary gland cancer	1.52e-05	2.09e-05	CbGpPWpGaD
Regorafenib—KIT—Immune System—HRAS—salivary gland cancer	1.51e-05	2.08e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—PIK3CA—salivary gland cancer	1.5e-05	2.07e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—PTEN—salivary gland cancer	1.49e-05	2.06e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	1.47e-05	2.03e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—CCND1—salivary gland cancer	1.47e-05	2.02e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—CCND1—salivary gland cancer	1.46e-05	2.02e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—EP300—salivary gland cancer	1.45e-05	2e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—PIK3CA—salivary gland cancer	1.44e-05	1.98e-05	CbGpPWpGaD
Regorafenib—FGFR1—Immune System—HRAS—salivary gland cancer	1.43e-05	1.97e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—PIK3CA—salivary gland cancer	1.43e-05	1.97e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Immune System—HRAS—salivary gland cancer	1.43e-05	1.96e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—NUP62—salivary gland cancer	1.42e-05	1.96e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—EP300—salivary gland cancer	1.42e-05	1.96e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—PIK3CA—salivary gland cancer	1.42e-05	1.96e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—PTEN—salivary gland cancer	1.42e-05	1.95e-05	CbGpPWpGaD
Regorafenib—FGFR2—Disease—HRAS—salivary gland cancer	1.42e-05	1.95e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—PTEN—salivary gland cancer	1.41e-05	1.95e-05	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—VCAN—salivary gland cancer	1.41e-05	1.95e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	1.4e-05	1.93e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PTEN—salivary gland cancer	1.39e-05	1.92e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PTEN—salivary gland cancer	1.39e-05	1.92e-05	CbGpPWpGaD
Regorafenib—KIT—Disease—HRAS—salivary gland cancer	1.39e-05	1.92e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—TP53—salivary gland cancer	1.39e-05	1.92e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—PIK3CA—salivary gland cancer	1.39e-05	1.91e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—PIK3CA—salivary gland cancer	1.36e-05	1.87e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—PIK3CA—salivary gland cancer	1.35e-05	1.87e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—PIK3CA—salivary gland cancer	1.35e-05	1.86e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—EP300—salivary gland cancer	1.35e-05	1.86e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—EP300—salivary gland cancer	1.35e-05	1.86e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—salivary gland cancer	1.34e-05	1.85e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—EP300—salivary gland cancer	1.33e-05	1.83e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—EP300—salivary gland cancer	1.33e-05	1.83e-05	CbGpPWpGaD
Regorafenib—NTRK1—Signaling Pathways—HRAS—salivary gland cancer	1.33e-05	1.83e-05	CbGpPWpGaD
Regorafenib—FGFR1—Disease—HRAS—salivary gland cancer	1.32e-05	1.82e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—CCND1—salivary gland cancer	1.32e-05	1.82e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Disease—HRAS—salivary gland cancer	1.32e-05	1.81e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—TP53—salivary gland cancer	1.31e-05	1.81e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Immune System—HRAS—salivary gland cancer	1.28e-05	1.77e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—PIK3CA—salivary gland cancer	1.28e-05	1.77e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—salivary gland cancer	1.28e-05	1.76e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PTEN—salivary gland cancer	1.27e-05	1.75e-05	CbGpPWpGaD
Regorafenib—KDR—Signaling Pathways—HRAS—salivary gland cancer	1.26e-05	1.73e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling by GPCR—HRAS—salivary gland cancer	1.25e-05	1.73e-05	CbGpPWpGaD
Regorafenib—ABL1—Immune System—HRAS—salivary gland cancer	1.25e-05	1.72e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—PIK3CA—salivary gland cancer	1.24e-05	1.71e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—CREBBP—salivary gland cancer	1.21e-05	1.67e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—EP300—salivary gland cancer	1.21e-05	1.67e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Disease—HRAS—salivary gland cancer	1.19e-05	1.63e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PTEN—salivary gland cancer	1.18e-05	1.63e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—CCND1—salivary gland cancer	1.18e-05	1.62e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—PIK3CA—salivary gland cancer	1.17e-05	1.61e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	1.16e-05	1.6e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—PIK3CA—salivary gland cancer	1.16e-05	1.59e-05	CbGpPWpGaD
Regorafenib—RAF1—Immune System—HRAS—salivary gland cancer	1.15e-05	1.58e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—PIK3CA—salivary gland cancer	1.14e-05	1.57e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PTEN—salivary gland cancer	1.13e-05	1.56e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—TP53—salivary gland cancer	1.13e-05	1.56e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—EP300—salivary gland cancer	1.13e-05	1.55e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—TP53—salivary gland cancer	1.12e-05	1.54e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—EP300—salivary gland cancer	1.08e-05	1.49e-05	CbGpPWpGaD
Regorafenib—MAPK11—Signaling Pathways—HRAS—salivary gland cancer	1.08e-05	1.49e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—PIK3CA—salivary gland cancer	1.07e-05	1.48e-05	CbGpPWpGaD
Regorafenib—BRAF—Signaling Pathways—HRAS—salivary gland cancer	1.07e-05	1.47e-05	CbGpPWpGaD
Regorafenib—RAF1—Disease—HRAS—salivary gland cancer	1.06e-05	1.46e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—PIK3CA—salivary gland cancer	1.05e-05	1.45e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	1.04e-05	1.43e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—TP53—salivary gland cancer	1.04e-05	1.43e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—CREBBP—salivary gland cancer	1.03e-05	1.42e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—TP53—salivary gland cancer	1.02e-05	1.4e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—PIK3CA—salivary gland cancer	9.99e-06	1.38e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—PIK3CA—salivary gland cancer	9.97e-06	1.37e-05	CbGpPWpGaD
Regorafenib—FGFR2—Signaling Pathways—HRAS—salivary gland cancer	9.92e-06	1.37e-05	CbGpPWpGaD
Regorafenib—UGT1A9—Metabolism—PIK3CA—salivary gland cancer	9.84e-06	1.36e-05	CbGpPWpGaD
Regorafenib—UGT1A1—Metabolism—PIK3CA—salivary gland cancer	9.84e-06	1.36e-05	CbGpPWpGaD
Regorafenib—KIT—Signaling Pathways—HRAS—salivary gland cancer	9.74e-06	1.34e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—TP53—salivary gland cancer	9.67e-06	1.33e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—TP53—salivary gland cancer	9.64e-06	1.33e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—salivary gland cancer	9.47e-06	1.3e-05	CbGpPWpGaD
Regorafenib—FGFR1—Signaling Pathways—HRAS—salivary gland cancer	9.25e-06	1.27e-05	CbGpPWpGaD
Regorafenib—PDGFRA—Signaling Pathways—HRAS—salivary gland cancer	9.22e-06	1.27e-05	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—CREBBP—salivary gland cancer	9.18e-06	1.26e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—PIK3CA—salivary gland cancer	8.98e-06	1.24e-05	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—CREBBP—salivary gland cancer	8.96e-06	1.23e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—TP53—salivary gland cancer	8.69e-06	1.2e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PTEN—salivary gland cancer	8.67e-06	1.19e-05	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—CREBBP—salivary gland cancer	8.37e-06	1.15e-05	CbGpPWpGaD
Regorafenib—ABCG2—Metabolism—PIK3CA—salivary gland cancer	8.35e-06	1.15e-05	CbGpPWpGaD
Regorafenib—PDGFRB—Signaling Pathways—HRAS—salivary gland cancer	8.31e-06	1.14e-05	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—EP300—salivary gland cancer	8.27e-06	1.14e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—PIK3CA—salivary gland cancer	8e-06	1.1e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—TP53—salivary gland cancer	7.74e-06	1.07e-05	CbGpPWpGaD
Regorafenib—RAF1—Signaling Pathways—HRAS—salivary gland cancer	7.4e-06	1.02e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PTEN—salivary gland cancer	7.34e-06	1.01e-05	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—EP300—salivary gland cancer	7e-06	9.65e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PTEN—salivary gland cancer	6.56e-06	9.03e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PTEN—salivary gland cancer	6.4e-06	8.81e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—EP300—salivary gland cancer	6.25e-06	8.61e-06	CbGpPWpGaD
Regorafenib—CYP2B6—Metabolism—PIK3CA—salivary gland cancer	6.12e-06	8.43e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—EP300—salivary gland cancer	6.1e-06	8.41e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PTEN—salivary gland cancer	5.98e-06	8.23e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—EP300—salivary gland cancer	5.7e-06	7.85e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—CREBBP—salivary gland cancer	5.52e-06	7.6e-06	CbGpPWpGaD
Regorafenib—CYP2C8—Metabolism—PIK3CA—salivary gland cancer	5.18e-06	7.14e-06	CbGpPWpGaD
Regorafenib—CYP2C19—Metabolism—PIK3CA—salivary gland cancer	4.62e-06	6.37e-06	CbGpPWpGaD
Regorafenib—ABCB1—Metabolism—PIK3CA—salivary gland cancer	4.51e-06	6.22e-06	CbGpPWpGaD
Regorafenib—CYP2C9—Metabolism—PIK3CA—salivary gland cancer	4.22e-06	5.81e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PTEN—salivary gland cancer	3.94e-06	5.43e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—EP300—salivary gland cancer	3.76e-06	5.18e-06	CbGpPWpGaD
Regorafenib—CYP3A4—Metabolism—PIK3CA—salivary gland cancer	2.78e-06	3.83e-06	CbGpPWpGaD
